HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

A bill to ensure NH’s Medicaid program doesn’t pay for circumcisions unless medically necessary was approved by the House by ...

Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Measles is unlike other childhood viruses. In severe cases, it can cause pneumonia. About 1 in 1,000 patients develops encephalitis.

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...